Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Patrick W. Mellors, Moritz Binder, Francis K. Buadi, Martha Lacy, Morie Gertz, Angela Dispenzieri, Suzanne R. Hayman, Prashant Kapoor, Wilson Gonsalves, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Taxiarchis Kourelis, Rahma Warsame, Steven R. Zeldenrust, John A. Lust, Nelson Leung, Ronald S. Go, Robert A. Kyle, S Vincent RajkumarShaji K Kumar

Research output: Contribution to journalArticle

Abstract

The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019

Fingerprint

Multiple Myeloma
Thrombocytopenia
Disease-Free Survival
Survival
Proteasome Inhibitors
Immunologic Factors
Platelet Count
Therapeutics

Keywords

  • Multiple myeloma
  • prognosis
  • response
  • survival
  • thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. / Mellors, Patrick W.; Binder, Moritz; Buadi, Francis K.; Lacy, Martha; Gertz, Morie; Dispenzieri, Angela; Hayman, Suzanne R.; Kapoor, Prashant; Gonsalves, Wilson; Hwa, Yi L.; Fonder, Amie; Hobbs, Miriam; Kourelis, Taxiarchis; Warsame, Rahma; Zeldenrust, Steven R.; Lust, John A.; Leung, Nelson; Go, Ronald S.; Kyle, Robert A.; Rajkumar, S Vincent; Kumar, Shaji K.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Mellors, Patrick W. ; Binder, Moritz ; Buadi, Francis K. ; Lacy, Martha ; Gertz, Morie ; Dispenzieri, Angela ; Hayman, Suzanne R. ; Kapoor, Prashant ; Gonsalves, Wilson ; Hwa, Yi L. ; Fonder, Amie ; Hobbs, Miriam ; Kourelis, Taxiarchis ; Warsame, Rahma ; Zeldenrust, Steven R. ; Lust, John A. ; Leung, Nelson ; Go, Ronald S. ; Kyle, Robert A. ; Rajkumar, S Vincent ; Kumar, Shaji K. / Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. In: Leukemia and Lymphoma. 2019.
@article{9bfc7075feac48cbb1a39ddba5cc6b06,
title = "Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma",
abstract = "The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95{\%} CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95{\%} CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95{\%} CI 3.02–9.00) and 8.43 years (95{\%} CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70{\%} from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.",
keywords = "Multiple myeloma, prognosis, response, survival, thrombocytopenia",
author = "Mellors, {Patrick W.} and Moritz Binder and Buadi, {Francis K.} and Martha Lacy and Morie Gertz and Angela Dispenzieri and Hayman, {Suzanne R.} and Prashant Kapoor and Wilson Gonsalves and Hwa, {Yi L.} and Amie Fonder and Miriam Hobbs and Taxiarchis Kourelis and Rahma Warsame and Zeldenrust, {Steven R.} and Lust, {John A.} and Nelson Leung and Go, {Ronald S.} and Kyle, {Robert A.} and Rajkumar, {S Vincent} and Kumar, {Shaji K}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1613536",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

AU - Mellors, Patrick W.

AU - Binder, Moritz

AU - Buadi, Francis K.

AU - Lacy, Martha

AU - Gertz, Morie

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Kapoor, Prashant

AU - Gonsalves, Wilson

AU - Hwa, Yi L.

AU - Fonder, Amie

AU - Hobbs, Miriam

AU - Kourelis, Taxiarchis

AU - Warsame, Rahma

AU - Zeldenrust, Steven R.

AU - Lust, John A.

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

AU - Kumar, Shaji K

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

AB - The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100,000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100,000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not (p =.042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively (p =.030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.

KW - Multiple myeloma

KW - prognosis

KW - response

KW - survival

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85066094519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066094519&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1613536

DO - 10.1080/10428194.2019.1613536

M3 - Article

AN - SCOPUS:85066094519

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -